Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus XELOX in resectable stage III colon cancer
NCT07156682Phase 2Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in colon cancer, sponsored by Qilu Hospital of Shandong University. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT07156682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07156682.